BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Oruka Therapeutics Inc

ORKANASDAQ
Trade with Public
Trade with Public
$82.15
-2.04-2.42%
가까이에: Sep 29, 5:00 PM EST
$81.00
-1.15-1.4%
시간외: 5:24 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Oruka Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oruka Therapeutics (ORKA).

Price Target Range — 9 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$87Upside to Avg. PT+7.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026WedbushMartin Fan MaintainedOutperform$165
Sep 24, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$120
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved